Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Citi Biopharma Back-to-School Summit on
Wednesday, September 3 rd -
Cantor Global Healthcare Conference 2025-
Company presentation -
Thursday, September 4 th starting at3:20 p.m. ET
-
Company presentation -
-
Morgan Stanley 23nd Annual Global Healthcare Conference
-
Company presentation -
Monday, September 8 th starting at8:30 a.m. ET
-
Company presentation -
-
Baird 2025 Global Healthcare Conference on
Tuesday, September 9 th -
H.C. Wainwright 27th AnnualGlobal Investment Conference -
Company presentation -
Wednesday, September 10 th starting at10:00 a.m. ET
-
Company presentation -
Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.
About
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases.
Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827209333/en/
Investor Contacts:
ir@mirumpharma.com
Media Contact:
BBlatstein@spectrumscience.com
Source: